Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aptevo (Details)

v3.23.2
Royalty and Commercial Payment Purchase Agreements - Aptevo (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Mar. 29, 2023
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Agreements              
Long-term royalty and commercial payment receivables   $ 72,232 $ 72,232 $ 72,232     $ 63,683
Payments of consideration under RPAs, AAAs and CPPAs       14,650 $ 5,000    
Contingent consideration under RPAs, AAAs and CPPAs   1,000 1,000 1,000     75
Receipts under RPAs, AAAs and CPPAs       2,934      
Short-term royalty and commercial payment receivables   4,958 4,958 4,958     $ 2,366
Aptevo              
Agreements              
Reduction in long-term royalty receivable balance due to receipt of payment       568      
Aptevo | Commercial Payment Purchase Agreement              
Agreements              
Maximum milestone payments entitled to receive $ 5,300            
Long-term royalty and commercial payment receivables 9,700            
Payments of consideration under RPAs, AAAs and CPPAs 9,600            
Contingent consideration under RPAs, AAAs and CPPAs 50 0 0 0   $ 50  
Commercial payments attributable to net sales threshold $ 500            
Reduction in long-term royalty receivable balance due to receipt of payment   600          
Short-term royalty and commercial payment receivables   0 0 0      
Amount of allowance for credit losses   0 0 $ 0      
Aptevo | Commercial Payment Purchase Agreement | Minimum              
Agreements              
Receipts under RPAs, AAAs and CPPAs     $ 500        
Medexus | Commercial Payment Purchase Agreement              
Agreements              
Receipts under RPAs, AAAs and CPPAs   $ 600